Company: ZVRA
Filing Date: 2025-04-07
Form Type: 8-K
Source: 0001193125-25-073991
Chunk: 0

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-07
Form: 8-K
Item: Item 2.01
Chunk 0
---
Item 2.01      Completion of Acquisition or Disposition of Assets.  

On April 1, 2025, Zevra Therapeutics, Inc. (the “ Company”) completed the previously disclosed sale (the “ Asset Sale”) of its Rare Pediatric Disease Priority Review Voucher (“ PRV”) to the buyer. The Company was awarded the voucher under a U. S. Food and Drug Administration (“ FDA”) program intended to encourage the development of certain rare pediatric disease product applications. The Company received the PRV when MIPLYFFA (arimoclomol) was approved by the FDA to be used in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.

The Asset Sale was completed pursuant to the terms of an asset purchase agreement, dated February 26, 2025 (the “ PRV Transfer Agreement”). Pursuant to the PRV Transfer Agreement, the Company received gross proceeds of $150.0 million from the buyer upon the closing of the Asset Sale.

The foregoing description of the PRV Transfer Agreement does not purport to be complete and is qualified in its entirety by the full text of the PRV Transfer Agreement.